エレクトロカウテリーを避ける:モース微細手術における手術前出血に対する静止剤
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。局所用血液静止剤は,特に血液を薄める薬を服用している患者では,モース手術中の出血を効果的に軽減します. これらの薬剤は,手術後の静止状態の改善に有望であり,さらなる研究が必要である.
科学分野
- 皮膚科 外科
- 手術による血液静止
- 薬理学について
背景
- 血液出血はモフス微細手術で よくある合併症です
- 抗凝固剤と抗血小板剤の使用が増加すると,出血のリスクが増加します.
- モフス手術で効果的な手術前静止策が必要である.
研究 の 目的
- モフス手術の局所的/局所的血静止剤に関する文献を体系的にレビューする.
- 補足用血液静止剤の有効性と安全性を評価する.
- モーホスの処置中に出血を軽減する剤を特定する.
主な方法
- 2024年3月までの体系的な文献検索 (PubMed,Scopus,Cochrane,EMBASE)
- 局所的または局所的に注射される血液静止剤に関するオリジナルの研究を含める.
- 458人の患者を対象とした7つの研究の分析
主要な成果
- 評価された薬剤には,トランキサム酸,ブリモニジンゲル,血静性粉末,微孔性ポリサッカリド材料が含まれていた.
- 薬剤は一般的に患者によってよく耐える.
- 術後の出血の減少が観察されました.
結論
- 局所的に投与される静止剤は,モース手術における出血制御の有望な補助剤です.
- これらの薬剤は,高リスクの出血患者にとって特に有益です.
- さらに大規模な制御研究が推奨されます.
関連する概念動画
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
The first is the irregular texture of blood vessels, which can...